Cure My Disease

Don't miss your cure!

 Log in / Sign up

DNA test may improve depression treatment in cancer patients

NCT ID NCT03674138

Symptom relief Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether using a person's DNA to pick an antidepressant works better than usual care for cancer patients with depression or anxiety. About 99 adults with cancer took part. Half got a DNA-guided choice of medication, and the other half got standard care. Researchers then compared changes in depression, anxiety, and quality of life between the two groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

99 people

The number who actually took part.

Started

Sep 2018

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with a cancer diagnosis * Be 18 years of age or older * Patients who rate depression or anxiety \> 5 based on a 10 point scale * Patients expected to live greater than 6 months * Serum bilirubin and creatinine \< 1.5x upper limit of normal * AST and ALT \< 3 times upper limit of normal * Willing and able to provide written informed consent * Able to complete self-assessment questionnaires Exclusion Criteria: * Patients not diagnosed with cancer * Antidepressant prescribing performed by a non-Moffitt psychiatrist after enrollment onto the clinical trial * Known Pregnancy * History of liver or allogenic stem cell transplant * Patients with a known cognitive impairment (e.g., delirium, dementia, etc.) or psychological impairment (e.g., schizophrenia, bipolar disease, etc.) other than depressive and anxiety symptoms.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anxiety are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anxiety anxiety disorder cancer Depression depressive disorder generalized anxiety disorder major depressive disorder neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anxiety Cancer Depression Depressive disorder Generalized anxiety disorder Major depressive disorder

Contacts and locations

Locations

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.